Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cilostazol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA) |
| 2 | ACTIVE_COMPARATOR | Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA) |
| Name | Type | Description |
|---|---|---|
| Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA) | DRUG | - |
| Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Cilostazol is a small molecule being investigated for the treatment of Pain. It is currently in Phase 1 clinical development. The drug is being studied to assess its relative bioavailability under fasting conditions. Cilostazol is an investigational drug and has not been approved for this indication.
Cilostazol is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate the drug's pharmacokinetic properties in the context of pain management.
Cilostazol is currently in Phase 1 clinical development. The drug is being studied for the treatment of Pain. It is an investigational drug, meaning it has not yet received regulatory approval and is still undergoing clinical evaluation to determine its safety and efficacy.
Cilostazol has one completed clinical trial registered under NCT00881231. This Phase 1 study, titled 'To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions,' enrolled 26 participants and was designed to evaluate the drug's bioavailability. The trial was active-controlled and randomized.
Cilostazol is a distinct drug entity and is not known to be the same as any other drug. It is being developed by Novartis AG for the treatment of Pain. The drug is currently in Phase 1 clinical trials, and no alternative names have been associated with it in the available data.